New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

STAFF SCIENTIST 1, Quantitative Molecular Biological Physics
The National Library of Medicine (NLM) ’s National Center for Biotechnology Information (NCBI) is recruiting for a Staff Scientist 1 in the Computational Biology Branch (CBB) that will contribute to NCBI’s mission to conduct research on fundamental biomedical problems at the molecular level using mathematical and computational method s. NLM is a component of the National Institutes of Health (NIH), part of the Department of Health and Human Services (DHHS). (Source: NLM General Announcements)
Source: NLM General Announcements - May 5, 2022 Category: Databases & Libraries Source Type: news

NCBI Posters at the Biology of Genomes Meeting
May 10-14, 2022 We are looking forward to the Biology of Genomes meeting, which will focus on “DNA sequence variation and its role in molecular evolution, population genetics and complex diseases, comparative genomics, large-scale studies of gene and protein expression, and genomic approaches to ecological systems.” NCBI will present three posters to highlight our Comparative … Continue reading NCBI Posters at the Biology of Genomes Meeting → The post NCBI Posters at the Biology of Genomes Meeting appeared first on NCBI Insights. (Source: NCBI Insights)
Source: NCBI Insights - May 3, 2022 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New CGR dbGaP Allele Frequency Aggregator (ALFA) Source Type: news

The New Science of Forgetting
A baby zebrafish is just half the size of a pea. A recent look inside its transparent brain, however, offers clues to the far bigger mystery of how we remember—and how we forget. In an experiment that yielded insights into memory and the brain, a team of researchers at the University of Southern California taught the tiny creature to associate a bright light with a flash of heat, a temperature change the fish responded to by trying to swim away. Using a custom-designed microscope, the team then captured images of the animals’ brains in the moments before and after they learned to associate the light and the hea...
Source: TIME: Health - April 28, 2022 Category: Consumer Health News Authors: Corinne Purtill Tags: Uncategorized feature healthscienceclimate Neuroscience Source Type: news

Unexpected protein could play role in common brain disorder
Scientists have known for years that amyloid fibrils — fibrous, ropelike structures formed by closely linked protein molecules — are present in the brains of patients with Alzheimer’s and Parkinson’s diseases and likely play a role in the progression of these disorders.  Now, UCLA biochemists have discovered such fibrils in the brains of people with a form of frontotemporal lobar degeneration, or FTLD, the most common neurodegenerative disorder after Alzheimer ’s and Parkinson’s. But surprisingly, the type of protein they expected to find in these potentially harmful fibrils wasn’t there at all; instead, a l...
Source: UCLA Newsroom: Health Sciences - April 19, 2022 Category: Universities & Medical Training Source Type: news

NLM Collaboration Improves Standards for Reporting Clinical Genomics Variants
The National Library of Medicine ’s (NLM) National Center for Biotechnology Information (NCBI) and the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) have released a set of standard transcripts for 99% of human protein coding genes and 99.8% of genes of clinical relevance. This set, part of the Matched Annotation from NCBI and EMBL-EBI (MANE) collection, harmonizes transcript and protein sets produced by this joint genome annotation effort. (Source: NLM General Announcements)
Source: NLM General Announcements - April 14, 2022 Category: Databases & Libraries Source Type: news

UCLA-led team creates first comprehensive map of human blood stem cell development
UCLA scientistsand colleagues have created a first-of-its-kind roadmap that traces each step in the development of blood stem cells in the human embryo, providing scientists with a blueprint for producing fully functional blood stem cells in the lab.The research,published todayin the journal Nature, could help expand treatment options for blood cancers like leukemia and inherited blood disorders such as sickle cell disease, saidDr. Hanna Mikkolaof theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, who led the study.Blood stem cells, also called hematopoietic stem cells, have the abilit...
Source: UCLA Newsroom: Health Sciences - April 13, 2022 Category: Universities & Medical Training Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news

Patients with Covid and flu double the risk of dying, say scientists
There have been calls for those hospitalised with the coronavirus to be routinely test for influenza after new research revealed an increased mortality rate for those with both conditionsSee all our coronavirus coverageCovid-19 patients who have been hospitalised should also be routinely tested for flu, researchers have said. The call was made after the publication of a paper in the medical journal theLancet that revealed having both conditions more than doubles the risk of a patient dying.Scientists also discovered that individuals who had contracted both Sars-CoV-2, the virus that causes Covid-19, and influenza viruses w...
Source: Guardian Unlimited Science - March 27, 2022 Category: Science Authors: Robin McKie Tags: Coronavirus Infectious diseases Medical research Science Immunology Health Biochemistry and molecular biology Source Type: news

CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Media News - March 25, 2022 Category: Pharmaceuticals Source Type: news

Researchers show protein controls process that goes awry in Parkinson ’s disease
As scientists work toward finding a cure for Parkinson ’s disease, one line of research that has emerged focuses on mitochondria, the structures within cells that make energy. The health of those structures is maintained through a quality control system that balances two opposite processes: fission — one mitochondrion splitting in two — and fusion — two becoming one.When there ’s a problem with fission, that system is thrown out of balance. The consequences can include neurodegenerative diseases, such as Parkinson’s disease, and other serious conditions.For years, scientists have known that one particular prote...
Source: UCLA Newsroom: Health Sciences - March 24, 2022 Category: Universities & Medical Training Source Type: news

Potential glioblastoma treatment has roots in UCLA graduate research
A potential new treatment for glioblastoma that recently received approval for clinical trials not only was developed by three UCLA faculty members but also traces its roots back to 2005, when one of the researchers was a UCLA graduate student.The oral medication, a small molecule called ERAS-801, targets a rogue gene found in approximately 60% of people with the aggressive form of brain cancer. Developed by UCLA professors David Nathanson, Michael Jung and Dr. Timothy Cloughesy, the drug would provide a  complement to existing treatments — surgery, radiation and chemotherapy.In December, ERAS-801 received a go-ahead fr...
Source: UCLA Newsroom: Health Sciences - March 15, 2022 Category: Universities & Medical Training Source Type: news

Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer
WEDNESDAY, March 9, 2022 -- Fecal microbiota-based screening seems feasible for early detection of pancreatic ductal adenocarcinoma (PDAC), according to a study published online March 8 in Gut. Ece Kartal, Ph.D., from the European Molecular Biology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2022 Category: Pharmaceuticals Source Type: news